Journal of Clinical Oncology

Juva Life Files Patent on Family of Non-Cannabinoid Small Molecules Targeting Consumer and Pharma Inflammatory Indications

Retrieved on: 
Thursday, October 14, 2021
Journal, American College, Literature, Surgical oncology, Surgery, CSE, Breast cancer, Executive Committee, The New England Journal of Medicine, Society, Knowledge, Therapy, Annals of Surgical Oncology, USPTO, JAMA, American Medical Association, United States Patent and Trademark Office, Chemistry, Board of directors, American Society of Breast Surgeons, American Board of Surgery, Inflammation, News, Annual general meeting, American Board of Commissioners for Foreign Missions, National academy, GLOBE, Journal of Clinical Oncology, National Academies of Sciences, Engineering, and Medicine, Patent, THE, S-1 Executive Committee, Company, Fellowship of the Royal Colleges of Surgeons, Oxidative stress, Board, Research, BOARD, Melanoma, Pharmaceutical industry, Management

JUVA-19 is a non-cannabinoid small molecule isolated from cannabis with previous unappreciated broad spectrum anti-inflammatory properties.

Key Points: 
  • JUVA-19 is a non-cannabinoid small molecule isolated from cannabis with previous unappreciated broad spectrum anti-inflammatory properties.
  • Additionally, the company has identified candidate targets consistent with the regulation of oxidative stress and inflammation.
  • Juva Life is availing itself of the significant body of literature suggestive of therapeutic benefits of cannabis coupled to modern drug discovery and deep learning tools.
  • The companys strategy is to develop natural and semi-synthetic compositions alone and in combination for the consumer anti-inflammatory marketplace, and in parallel chemically optimize compositions for select pharmaceutical indications.

Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal™ Blood Test to Predict Recurrence Across Early-Stage Cancers

Retrieved on: 
Tuesday, October 5, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Blood, Veni, vidi, vici, Frontiers Media, Result, MRD, Research, ORACLE, Colorectal cancer, Observation, Clinical Cancer Research, Recurrence, Annual report, Helmy Eltoukhy, Security (finance), Benefit, Use, Health, Circulating tumor DNA, DNA, U.S. Securities and Exchange Commission, Cancer, Methylation, Adjuvant, III, PEGASUS, Marker, MD, JAMA Oncology, COBRA, Disease, Financial condition report, Observational study, Science Translational Medicine, GH, Analysis, Risk, Technology, Journal of Clinical Oncology, Parikh's theorem, Plasma, Neoplasm, Medical imaging, Wood drying

The ORACLE study adds to currently underway clinical studies ( COBRA , ACT-3 , PEGASUS ) evaluating the performance of the Guardant Reveal blood test in patients with early-stage cancer.

Key Points: 
  • The ORACLE study adds to currently underway clinical studies ( COBRA , ACT-3 , PEGASUS ) evaluating the performance of the Guardant Reveal blood test in patients with early-stage cancer.
  • We believe our blood-only test can be a powerful and streamlined decision-making tool for oncologists managing patients with early-stage cancers, said Helmy Eltoukhy, Guardant Health Co-CEO.
  • The ORACLE study exemplifies our commitment to further demonstrating the utility of our blood tests to improve long-term clinical outcomes.
  • The Guardant Reveal test is the first blood-only liquid biopsy test that detects residual and recurrent disease from a simple blood draw.

Geron Corporation Reports Greater Than 90% Enrollment in IMerge Phase 3 and Expected Top-Line Results Accelerated to First Quarter of 2023

Retrieved on: 
Monday, August 16, 2021
Biotechnology, Pharmaceutical, Health, U.S. Securities and Exchange Commission, Clinical trial, Refractory, Achievement, European Hematology Association, Asterias, Ix, Research, Journal, RBC, ESA, Safety, Apoptosis, Corporation, Xi, Company, Private Securities Litigation Reform Act, Journal of Clinical Oncology, Relapse, Risk, Telephone, Geron Corporation, Lineage Cell Therapeutics, Microdeletion syndrome, LR, ID, JAK, Register, Fast Track, IDMC, Â, COVID-19, Pharmacokinetics, Bone marrow, MDS, Telomerase, Income, Intellectual property, OS, Disease, Survival, Patient, Webcast, Security (finance), EHA, Nasdaq, Vii, Pharmaceutical industry, Health insurance, Medical imaging, Vaccine, Lithium, Medicine, Imetelstat, IMerge Phase 3, IMpactMF, Geron, IMETELSTAT, IMERGE PHASE 3, IMPACTMF, GERON

In addition, the expected timing for top-line results in IMerge Phase 3 has been accelerated by three months to the first quarter of 2023, said John A. Scarlett, M.D., Chairman and Chief Executive Officer.

Key Points: 
  • In addition, the expected timing for top-line results in IMerge Phase 3 has been accelerated by three months to the first quarter of 2023, said John A. Scarlett, M.D., Chairman and Chief Executive Officer.
  • As of August 12, 2021, the Company had achieved 91% of the planned enrollment in IMerge Phase 3.
  • With the revised 12-month follow-up period for the primary analysis, the Company now projects that top-line results from IMerge Phase 3 will be available in the first quarter of 2023.
  • For further information about IMerge Phase 3, including enrollment criteria, locations, and current status, please visit ClinicalTrials.gov/NCT02598661.